ProKidney Corp, a biotech company, is making progress in developing therapies that use patients’ own cells to repair and restore diseased kidneys, potentially reducing the need for dialysis or transplants.

ProKidney Corp’s stock experiences a volatile trading session after announcing FDA alignment for its flagship product, rilparencel, a therapy for chronic kidney disease.

ProKidney Corp’s stock experiences significant volatility after securing FDA alignment on its therapy rilparencel, a promising treatment for chronic kidney disease.

ProKidney Corp’s stock price surged after positive trial results for its kidney disease treatment, with the company’s stock price increasing by 60% on one day and a raised price target by Citi.

ProKidney Corp, a biotech company, has experienced significant stock price fluctuations, but its innovative approach to kidney disease treatment remains a key differentiator in the healthcare sector.